Appetite suppressing drugs sibutramine

Centrally acting appetite suppressant drugs approved for longer term use Sibutramine (Meridia)... 

The FDA approves the prescription appetite suppressant sibutramine (brand name Meridia), the first prescription weight loss drug of its kind. 

The adverse effects of amphetamine and related sympathomimetic appetite suppressants are well documented. All of these agents are classified by the U.S. Drug Enforcement Administration (DEA) as controlled substances (classes II-IV) according to their potential for causing addiction (see Table 15.4). Class II agents such as amphetamine are highly abused, with prescription restricted to speeial circumstances class TV anorectic drugs such as sibutramine, phentermine, di-ethylpropion, and mazindol have minimal abuse potential. 

On theoretical grounds the manufacturers contraindicate the concurrent use of sibutramine with MAOIs, and they say that it should not be given with serotonei ic drugs because of the risk of the serious serotonin syndrome. The manufacturers say that the use of sibutramine with other centrally acting appetite suppressants is contraindicated and they caution the use of cold and flu remedies. No clinically relevant interactions have been seen between sibutramine and cimetidine, and no interaction occurs with oral contraceptives. 

Cocaine metabolites were detected in nrine by solid phase extraction (SPE) IMS with detection limits of 10 and 4 ng/mL for BE and cocaethylene, respectively. The analytes are retained on the SPE cartridge, while salts and polar compounds that may interfere with the analysis remain in solntion. Sweat samples have also been examined by ion trap mobility spectrometry (ITMS), and traces of 6-acetylmorphine, heroin, and cocaine were detected. Not only illicit drugs can be detected by IMS, but also food additives or supplements that are undeclared, like the appetite suppressant sibutramine. ... 

---